scholarly journals Nimustine Hydrochloride

2020 ◽  
Author(s):  
2005 ◽  
Vol 72 (1) ◽  
pp. 57-62 ◽  
Author(s):  
Takao Watanabe ◽  
Yoichi Katayama ◽  
Atsuo Yoshino ◽  
Chikashi Fukaya ◽  
Takamitsu Yamamoto

1997 ◽  
Vol 24 (10) ◽  
pp. 682-683
Author(s):  
Yuko Takata ◽  
Shinobu Hayashi ◽  
Tomoya Ohno ◽  
Satoshi Dekio

2016 ◽  
Vol 130 (1) ◽  
pp. 165-170 ◽  
Author(s):  
Masashi Mizumoto ◽  
Tetsuya Yamamoto ◽  
Eiichi Ishikawa ◽  
Masahide Matsuda ◽  
Shingo Takano ◽  
...  

Skin Cancer ◽  
2001 ◽  
Vol 16 (2) ◽  
pp. 255-261
Author(s):  
Tadashi Umeda ◽  
Yuiro Hata ◽  
Hideo Iida ◽  
Hiroki Mori ◽  
Kazuyuki Tanaka ◽  
...  

2011 ◽  
Vol 7 (5) ◽  
pp. 522-526 ◽  
Author(s):  
Ryuta Saito ◽  
Yukihiko Sonoda ◽  
Toshihiro Kumabe ◽  
Ken-ichi Nagamatsu ◽  
Mika Watanabe ◽  
...  

This 13-year-old boy with a history of cranial irradiation for the CNS recurrence of acute lymphocytic leukemia developed a glioblastoma in the right cerebellum. Resection and chemo- and radiotherapy induced remission of the disease. However, recurrence was noted in the brainstem region 8 months later. Because no effective treatment was available for this recurrent lesion, the authors decided to use convection-enhanced delivery (CED) to infuse nimustine hydrochloride. On stereotactic insertion of the infusion cannula into the brainstem lesion, CED of nimustine hydrochloride was performed with real-time MR imaging to monitor the co-infused chelated gadolinium. The patient's preinfusion symptom of diplopia disappeared after treatment. Follow-up MR imaging revealed the response of the tumor. The authors report on a case of recurrent glioblastoma infiltrating the brainstem that regressed after CED of nimustine hydrochloride.


2012 ◽  
Vol 68 (3) ◽  
pp. o144-o148 ◽  
Author(s):  
Sándor L. Bekö ◽  
David Urmann ◽  
Andrea Lakatos ◽  
Clemens Glaubitz ◽  
Martin U. Schmidt

Nimustine hydrochloride [systematic name: 4-amino-5-({[N-(2-chloroethyl)-N-nitrosocarbamoyl]amino}methyl)-2-methylpyrimidin-1-ium chloride], C9H14ClN6O2+·Cl−, is a prodrug of CENU (chloroethylnitrosourea) and is used as a cytostatic agent in cancer therapy. Its crystal structure was determined from laboratory X-ray powder diffraction data. The protonation at an N atom of the pyrimidine ring was established by solid-state NMR spectroscopy.


Sign in / Sign up

Export Citation Format

Share Document